Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06734975 · ClinicalTrials.gov registry record · Phase 2
Effect of Superior Laryngeal Nerve Blocks on Patient Outcomes in Laryngeal Surgery
A Phase 2 study of Vocal Cord Disease and Vocal Cord Polyp, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06734975: Recruiting Phase 2 study of Vocal Cord Disease and Vocal Cord Polyp, sponsored by Rutgers, The State University of New Jersey.
NCT06734975 is a Phase 2 study of Vocal Cord Disease and Vocal Cord Polyp that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06734975, a Phase 2 study of Vocal Cord Disease and Vocal Cord Polyp, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients undergoing surgery on their vocal cord will either receive a numbing injection to their throat or a saline injection during surgery. Symptoms such as how much coughing or pain patients have after surgery, as well as whether patient's voice gets better will be interrogated.
Primary Outcome
We will record postoperative pain via the 100 mm visual analog scale (VAS). The minimum is 0, maximum is 100, and a higher score indicates more pain and thus a worse outcome.
Conditions Studied
Interventions
- DRUG Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)
- DRUG Superior laryngeal nerve block - Placebo (saline)
Study Locations (1)
New Jersey
- Rutgers New Jersey Medical School - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-07-11 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT06734975 shows while recruiting
NCT06734975 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 3 conditions, with Vocal Cord Disease appearing as the primary indexed condition, and to 2 interventions - of which Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension) is the first listed.
NCT06734975 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06734975 about?
NCT06734975 is a clinical study titled "Effect of Superior Laryngeal Nerve Blocks on Patient Outcomes in Laryngeal Surgery". Patients undergoing surgery on their vocal cord will either receive a numbing injection to their throat or a saline injection during surgery. Symptoms such as how much coughing or pain patients have after surgery, as well as whether patient's voice gets better will be interrogated.
What is the current status of trial NCT06734975?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2025-07-11. Estimated completion is 2026-12.
What conditions does trial NCT06734975 study?
This clinical trial studies the following conditions: Vocal Cord Disease, Vocal Cord Polyp, Vocal Cord Cyst.
What interventions are being tested in trial NCT06734975?
The interventions under investigation include: Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension) (DRUG), Superior laryngeal nerve block - Placebo (saline) (DRUG).
Who is sponsoring clinical trial NCT06734975?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06734975 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06734975's enrollment target sits among peer trials
28 1677th of 2000 higher than 305 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI